Medical devices, healthcare technology and the business of care
510(k) clearance · K252652

Disposable Syringes with Accessories for Power Injectors (900103T); Disposable Syringes with Accessories for Power Injectors (900103H); Disposable Syringes with Accessories for Power Injectors (801800H); Disposable Syringes with Accessories for Power Injectors (800099T); Disposable Syringes with Accessories for Power Injectors (800099H); Disposable Syringes with Accessories for Power Injectors (800096T); Disposable Syringes with Accessories for Power Injectors (800096H); Disposable Syr

Fortis Biosolutions Company Limited · Decision date May 14, 2026

FDA DECISIONK252652

What did the FDA decide?

FDA records K252652 as a 510(k) premarket notification, with a decision dated May 14, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
May 14, 2026

FDA source record

Regulatory record facts

Identifier
K252652
Regulatory pathway
510(k) premarket notification
Product code
DXT
Decision code
SESE
Decision date
May 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Injector And Syringe, Angiographic.

Product code
DXT
FDA device class
2

FDA decision timeline

  1. K252652 received

    Application receipt date recorded by FDA.

  2. K252652 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DXT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Fortis Biosolutions Company Limited

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Taoyuan City

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records